| Heading: |
NHS: Medical Records |
| Question ID: |
1786390 |
| UIN: |
39551 |
| House: |
Commons |
| Date tabled: |
2025-03-19 |
| Asking Member ID: |
4657 |
| Asking Member display name: |
Anneliese Dodds
|
| Asking Member handle: |
|
| Asking Member Twitter reference: |
Anneliese Dodds
|
| Member interest: |
false |
| Question text: |
To ask the Secretary of State for Health and Social Care, which projects using NHS data undertaken by (a) Novartis, (b) IQVIA, (c) AstraZeneca, (d) Merck, (e) Novo Nordisk, (f) GSK, (g) Roche and (h) Janssen-Cilag have adopted the (i) no value sharing, (i |
| Is named day: |
false |
| Date of holding answer: |
|
| Date answered: |
2025-03-26 |
| Date answer corrected: |
|
| Is holding answer: |
false |
| Is correcting answer: |
false |
| Answering Member ID: |
4444 |
| Answering Member display name: |
Karin Smyth
|
| Answering Member handle: |
karinsmyth
|
| Answering Member Twitter reference: |
@karinsmyth
|
| Correcting Member ID: |
|
| Correcting Member display name: |
|
| Correcting Member handle: |
|
| Correcting Member Twitter reference: |
|
| Answer text: |
The Department and the National Health Service in England are moving to a system of “data access as default” for secondary uses of NHS data, which is being supported by the implementation of Secure Data Environments (SDEs). This means that NHS data is inc... |
| Original answer text: |
|
| Comparable answer text: |
|
| Answering body ID: |
17 |
| Answering body name: |
Department of Health and Social Care |
| Tweeted: |
true |